Drug safety evaluation of defibrotide

Abstract

Introduction: Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of chemotherapeutic conditioning used in preparation for hematopoietic stem-cell transplantation (SCT). Defibrotide (DF) has been shown in Phase II and III trials to improve complete response in patients with severe VOD (sVOD). None of the articles, to date, provide a comprehensive review of the safety of DF in VOD and/or a range of other conditions.

Areas covered: This article reviews current clinical findings on DF, primarily in terms of safety for use in treatment and prophylaxis of VOD, and relevant safety data for its use in other diseases. The literature review was conducted using a PubMed search with the fixed term ‘defibrotide' in combination with ≥ 1 of ‘safety', ‘veno-occlusive disease' (with and without ‘treatment', ‘prevention'), ‘oncology', ‘myeloma', ‘microangiopathy', ‘anti-thrombotic' and ‘peripheral vascular disorder'. Related articles from the EBMT and ASH conference websites were also included.

Expert opinion: DF was well tolerated in majority of the studies. The safety profile of DF is largely favourable with toxicities comparable to control populations in the setting of SCT complicated by sVOD.

Keywords::

• anti-inflammatory
• antithrombotic
• defibrotide
• endothelial protective
• prevention
• profibrinolytic
• prophylaxis
• safety
• sinusoidal obstruction syndrome
• treatment
• veno-occlusive disease

Acknowledgements

Writing assistance was provided by S Aggarwal of ApotheCom ScopeMedical Ltd, sponsored by an unrestricted grant from Gentium SpA.

Notes